Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Figure 2 | Arthritis Research & Therapy

Figure 2

From: Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy

Figure 2

Consolidated Standards of Reporting Trials Statement (CONSORT) diagram for the pooled tophus-evaluable population. This population flowchart shows the disposition of all patients with baseline tophi pooled from the two randomized, placebo-controlled trials of pegloticase known as GOUT 1 and GOUT 2. OLE, open-label extension; RCT, randomized controlled trial.

Back to article page